Active-ingredient Dossier
Sildenafil Citrate
Active-ingredient Dossier for Sildenafil Citrate (phosphodiesterase type 5 inhibitor). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: SILDENAFIL
- Brand: VASAFIL
- Brand: REVATIO
- Brand: Sildenafil Wafer-ISPL
- Brand: Wafesil
- Brand: AMSILVIG
- Therapeutic area: Reproductive Health
- Therapeutic area: Cardiology
What is
Sildenafil Citrate Sildenafil Citrate is a phosphodiesterase type 5 inhibitor.
Australian brands containing
Sildenafil Citrate — SILDENAFIL — VASAFIL — REVATIO — APX-SILDENAFIL — AZULVIG — SILCAP — SILDATIO — SILDENACAP — SILDENAFIL SANDOZ — Sildenafil Wafer-ISPL — SILDENAFIL-DRLA
Therapeutic areas
Sildenafil Citrate is registered in three therapeutic areas: Urology (23 brands), Cardiology (5 brands), and Reproductive Health (2 brands).
Sponsor landscape
Sildenafil Citrate is marketed by eleven sponsors, including Arrotex Pharmaceuticals, iX Biopharma, AdiraMedica, Dr Reddys Laboratories, Viatris, and Accord Healthcare.
PBS and regulatory activity
Two brands containing Sildenafil Citrate have PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was recorded on 1 November 2006, and the latest AusPAR was published on 16 September 2011.